NEW YORK (Reuters Health) – In a postmortem study of patients with Alzheimer’s disease, diabetic subjects treated with both insulin and oral hypoglycemic agents had lower neuritic plaque…
NEW YORK (Reuters Health) – Patients with marked clinical fluctuation in neurologic status due to cerebral ischemia may benefit from thrombolytic therapy, researchers from Canada report in the…
Dr. Stephen Lane, DVM, explains Syringomyelia, a painful, neurological disease in canines that also has a counterpart in humans. References and Resources Heiss, J., et al. Elucidating the…
Among children presenting to the emergency department with headache, certain clinical characteristics might help identify those with headaches that are secondary to a life-threatening condition, according to recently…
In a recent study, diabetics who took both insulin and other medications for the disease had fewer plaques associated with Alzheimer’s disease than other patients. References and Resources…
Myriad Genetics, Inc. is discontinuing development of tarenflurbil, also known as Flurizan, after the investigational treatment for Alzheimer’s disease failed to achieve significance on the co-primary endpoints –…
Rasagiline 1 mg tablets slow the progression of Parkinson’s disease, according to Phase III trial data. From our partners at VerusMed VerusMed.com Sponsored by The Doctor’s Channel
The FDA has expanded indications for methylphenidate (Concerta) extended-release tablets to include adults aged 18 to 65 with ADHD. For more information visit: FDA Sponsored by The Doctor’s…
According to results of a multi-center, placebo-controlled phase IIb trial, patients treated with laquinimod, a new type of immumodulatory agent for relapsing-remitting MS, had a 40% reduction in…
The non-steroidal, anti-inflammatory drugs celecoxib and naproxen sodium do not improve cognitive function, ADAPT trial data indicate. From our partners at VerusMed: VerusMed.com Sponsored by The Doctor’s Channel